IGENICA
Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. They are the only biotherapeutic company that fully powers the ADC development spectrum from a clinically relevant approach to target and functional antibody discovery to ADC creation, accelerating development and the delivery of effective therapies to patients. Founded in 2009, Igenica is led by a proven team of leaders that have demonstrated succ... ess in antibody drug discovery, clinical development and commercialization. Their leadership team has played a seminal role in six out of the 36 currently approved antibody therapeutic products. Based in Burlingame, Calif., they are well-funded by a premier team of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures.
IGENICA
Industry:
Biotechnology Life Science Medical
Founded:
2009-01-01
Address:
Burlingame, California, United States
Country:
United States
Website Url:
http://www.igenica.com
Total Employee:
11+
Status:
Active
Contact:
6506974900
Total Funding:
80.6 M USD
Technology used in webpage:
Amazon Google Maps Google Maps API Amazon Virginia Region Amazon S3 CDN Amazon Elastic Load Balancing Amazon ELB North Virginia
Similar Organizations
CTI BioPharma
CTI BioPharma is a biopharmaceutical company developing oncology products for the treatment of cancer.
Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Advisor
Advisor
Board_member
Current Employees Featured
Robert D. Schreiber Co-Founder @ Igenica
Co-Founder
Hans van Houte Chief Scientific Officer @ Igenica
Chief Scientific Officer
John K. Celebi Chief Business Officer @ Igenica
Chief Business Officer
Founder
Investors List
National Institutes of Health
National Institutes of Health investment in Grant - Igenica
OrbiMed
OrbiMed investment in Series C - Igenica
Third Rock Ventures
Third Rock Ventures investment in Series C - Igenica
The Column Group
The Column Group investment in Series C - Igenica
5AM Ventures
5AM Ventures investment in Series C - Igenica
Third Rock Ventures
Third Rock Ventures investment in Series C - Igenica
5AM Ventures
5AM Ventures investment in Series C - Igenica
OrbiMed
OrbiMed investment in Series C - Igenica
The Column Group
The Column Group investment in Series C - Igenica
The Column Group
The Column Group investment in Series B - Igenica
Official Site Inspections
http://www.igenica.com Semrush global rank: 2.89 M Semrush visits lastest month: 5.61 K
- Host name: ec2-44-195-229-203.compute-1.amazonaws.com
- IP address: 44.195.229.203
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Igenica"
Igenica - Crunchbase Company Profile & Funding
Igenica is a biopharmaceutical company developing antibody-based therapeutics for the treatment of cancer.See details»
Online Delivery｜毎日の生活に必要なものを最短当日お届け
Online Delivery (オンラインデリバリーイグニカ)は、食料品から日用品まで毎日の生活に必要なものを「便利」「安全・安心」にお届けするサービスです。 ご自宅への配送の他、予約や …See details»
Igenica - VentureRadar
Igenica, Inc. is a biopharmaceutical company pioneering breakthrough antibody-based cancer medicines. The company has integrated innovative technology platforms to address the major …See details»
Igenica - EquityNet
Igenica is a biopharmaceutical company dedicated to the discovery and development of breakthrough antibody-based therapeutics for the treatment of cancer. Although recombinant …See details»
IGENICA INC Fund: A Comprehensive Overview – GP Track Record
Jan 29, 2025 IGENICA INC Fund is a distinguished investment fund, managed by a skilled general partner, and associated with significant entities in the biotechnology sector. This …See details»
Igenica Raises $24 Million - venturecapitaljournal.com
Jun 11, 2010 Igenica Inc., a developer of antibody-based cancer medicines, has raised $24 million in Series B funding. Return backers include The Column Group, OrbiMed Advisors and …See details»
Igenica Biotherapeutics, Inc.: Contact Details and Business Profile
Igenica Biotherapeutics, Inc. is a Biotechnology, Pharmaceuticals, and Drug Discovery company located in Burlingame, California with $8.40 Million in revenue and 3 employees. Find top …See details»
Igenica Inc. - BioCentury Company Profiles - BCIQ
Aug 9, 2022 Igenica Inc. - BioCentury Company Profiles for the biopharma industrySee details»
Igenica, Inc. Appoints Oncology Expert And Industry Veteran
Dec 17, 2013 Igenica, Inc., a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced …See details»
Igenica, Inc. Enters Into A Strategic Oncology Research ... - BioSpace
Oct 28, 2015 Igenica Biotherapeutics, Inc., a company focused on the discovery and development of innovative antibody-based therapies for the treatment of cancer, announced …See details»
Igenica - Contacts, Employees, Board Members, Advisors & Alumni
Igenica is a biopharmaceutical company developing antibody-based therapeutics for the treatment of cancer.See details»
Igenica Company Profile - Life Science Intelligence
Get a Demo and See the Full Profile Get a demo today to see profiles of Igenica plus 5771 other startups.Antibody-based cancer medicinesSee details»
Igenica Biotherapeutics - Products, Competitors, Financials, …
About Igenica Biotherapeutics Igenica is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. Igenica is the only …See details»
Pierre Fabre buys up Igenica preclinical I-O meds
May 24, 2017 Pierre Fabre, the second biggest biopharma in France (after Big Pharma Sanofi), is boosting its cancer pipeline with what it is dubbing “promising” immuno-oncology candidates …See details»
Igenica - Funding, Financials, Valuation & Investors - Crunchbase
Igenica is a biopharmaceutical company developing antibody-based therapeutics for the treatment of cancer.See details»
Igenica Biotherapeutics (immune oncology asset) - PitchBook
Information on acquisition, funding, investors, and executives for Igenica Biotherapeutics (immune oncology asset). Use the PitchBook Platform to explore the full profile.See details»
Igenica Culture | Comparably
Igenica Company Overview Igenica is a biopharmaceutical company developing antibody-based therapeutics for the treatment of cancer.See details»
Pierre Fabre Acquires Igenica Immuno-Oncology Assets
May 24, 2017 Pierre Fabre also did not disclose how many immuno-oncology candidates it acquired—but did say the most advanced of those is a preclinical asset “expected to be …See details»
Igenica to Advance mAb Platform with $33M Series C
Jun 13, 2012 Privately held Igenica Inc. hooked Third Rock Ventures LLC, which traditionally launches biotech start-ups, as lead investor in a $33 million Series C to propel initial …See details»
U.S.M.Hがデジタルブランド「ignica」で仕掛ける顧客体験の一大 …
食品スーパー3社を擁し全国に計530店舗を構えるユナイテッド・スーパーマーケット・ホールディングス（東京都／藤田元宏社長：以下、U.S.M.H）は、2020年に _ U.S.M.Hがデジタルブ …See details»